OTCMKTS:DCTHD Delcath Systems (DCTHD) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free DCTHD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.40▼$5.7450-Day Range N/A52-Week Range$1.22▼$63,000.00Volume220,934 shsAverage Volume771 shsMarket Capitalization$224,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Delcath Systems alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Delcath Systems Stock (OTCMKTS:DCTHD)Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.Read More Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry DCTHD Stock News HeadlinesMarch 21, 2024 | gurufocus.comDirector Gil Aharon Acquires 26,882 Shares of Delcath Systems Inc (DCTH)December 30, 2023 | benzinga.comDelcath Systems Stock (NASDAQ:DCTH) Insider TradesApril 24, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. December 30, 2023 | benzinga.comDelcath Systems Stock (NASDAQ:DCTH) Dividends: History, Yield and DatesAugust 31, 2023 | thestreet.comDelcath Liver Tumor Data ImproveAugust 15, 2023 | msn.comDelcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver TherapyAugust 11, 2023 | msn.comDelcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFAAugust 9, 2023 | msn.comDelcath Systems GAAP EPS of -$0.58 beats by $0.02, revenue of $0.5M misses by $0.24MApril 24, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. July 9, 2023 | thestreet.comDelcath Readies Pivotal Trial ResultsJune 19, 2023 | forbes.comBest iPad POS Systems Of 2023May 24, 2023 | msn.comHC Wainwright & Co. Reiterates Delcath Systems (DCTH) Buy RecommendationMay 15, 2023 | bbc.co.ukWhat is the digestive system?May 12, 2023 | thestreet.comDelcath: Safety Questions Behind FDA DelayMarch 27, 2023 | finance.yahoo.comDelcath Systems Announces up to $85 Million FinancingMarch 27, 2023 | markets.businessinsider.comDelcath Systems Inc. Q4 Loss increases, misses estimatesMarch 27, 2023 | finance.yahoo.comDelcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 27, 2023 | markets.businessinsider.comDelcath Announces FDA's Acceptance Of NDA Resubmission Of Hepzato KitFebruary 16, 2023 | markets.businessinsider.comDelcath Systems Announces Resubmission Of NDA For Hepzato KitDecember 15, 2022 | gurufocus.comAn Insider Just Bought Shares of Delcath Systems Inc; Could This Stock Be a Value Opportunity?November 8, 2022 | seekingalpha.comDelcath Systems slips despite Q3 beatSeptember 10, 2022 | seekingalpha.comDCTH Delcath Systems, Inc.August 10, 2022 | markets.businessinsider.comDelcath Systems Inc. Q2 Loss increases, misses estimatesJuly 27, 2022 | markets.businessinsider.comDelcath Systems to Host Second Quarter 2022 ResultsMarch 15, 2022 | benzinga.comDelcath Systems to Host Fourth Quarter and Full Year 2021 ResultsFebruary 4, 2022 | benzinga.comDelcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To LiverDecember 2, 2021 | benzinga.comDelcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data AnalysisSee More Headlines Receive DCTHD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2016Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:DCTHD Previous SymbolNASDAQ:DCTH CUSIPN/A CIKN/A Webwww.delcath.com Phone212-489-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,220,000.00 Net Margins-1,546.38% Pretax MarginN/A Return on EquityN/A Return on Assets-343.56% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.50 Sales & Book Value Annual Sales$3.41 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value($1,036.00) per share Price / Book-0.01Miscellaneous Outstanding Shares40,000Free FloatN/AMarket Cap$224,000.00 OptionableNot Optionable Beta-0.03 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesRoger G. Stoll Ph.D. (Age 74)Chairman of the Board Jennifer K. Simpson Ph.D. (Age 48)President, Chief Executive Officer, Director Barbra C. Keck (Age 39)Chief Financial Officer, Secretary John Purpura (Age 55)Executive Vice President - Global Head of Operations Simon C. Pedder Ph.D. (Age 56)Director William Dodge Rueckert (Age 64)Independent Director Marco Taglietti M.D. (Age 57)Independent Director More ExecutivesKey CompetitorsVerisante TechnologyOTCMKTS:VRSEFTodos MedicalOTCMKTS:TOMDFPresbiaOTCMKTS:LENSFMotus GINASDAQ:MOTSH-CYTEOTCMKTS:HCYTDView All Competitors DCTHD Stock Analysis - Frequently Asked Questions How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (OTCMKTS:DCTHD) released its quarterly earnings data on Friday, November, 11th. The medical device company reported ($231.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same period in the previous year, the company earned ($686.00) EPS. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. This page (OTCMKTS:DCTHD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
